GEP Capital Group, LLC (GEP), a Chinese-operated financial, advisory firm, assists qualified Chinese companies seeking Western capital for organic growth and complementary acquisitions. GEP’s private-to-public program is a standard reverse merger program, enabling the Chinese company to merge into an existing U.S. public shell, with the majority ownership transferring to the operating entity. An intrinsic difference from competing programs is the exemplary GEP due diligence program that qualifies and certifies these Chinese companies.

Headquartered in Beijing, GEP has completed 4 such reverse mergers since March 2006. These include Lotus Pharmaceuticals (LTUS), Gold Horse International (GHII), China Wind Systems (CWSI), and Genesis Pharmaceuticals (GTEC). In each case, GEP sourced and screened the private Chinese entity, conducted a pre-audit and pre-legal due diligence procedure, acquired Regulation 106 and tax relief approvals, and assisted the Chinese company in restyling to operate more like a Western enterprise. These newly-minted public companies boast a combined market cap exceeding $250 million.

GEP anticipates that it could complete an additional 4 private-to-public transformations this year, with an additional six candidates in its pipeline.

GEP hosted a China Investment Growth Forum, entitled "Mutual Growth Investment Program for Small and Medium Sized Chinese Companies", in Beijing on Tuesday, May 23, 2006. Held at the venerated Diao Yu Tai State Guest House, over 100 members of the national media attended along with government and industry dignitaries. GEP is recognized a leader amongst financial advisors in the Chinese business community.